Common Stock, $0.0001 par value per share
- Symbol
- IRD
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.02, 9.01 · 8-K
Opus Genetics, Inc.
IRDNASDAQEQUITYCurrent
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Opus Genetics, Inc. (the “Company”) and Ashwath Jayagopal have agreed that Dr. Jayagopal will transition from his role as the Company’s Chief Scientific and Development Officer, effective as of October 19, 2026 (the “Separation Date”).…
Company context
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.
Current securities
Historical securities (1)
Registered securities in this filing
Opus Genetics, Inc. · 8-K · Filed 2026-10-21
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
Opus Genetics, Inc. (the “Company”) and Ashwath Jayagopal have agreed that Dr. Jayagopal will transition from his role as the
Company’s Chief Scientific and Development Officer, effective as of October 19, 2026 (the “Separation Date”).
Effective on the Separation Date, the Company entered into a separation and release agreement with Dr. Jayagopal, which includes a
consulting agreement (together, the “Letter Agreement”), which provides for a six-month consulting arrangement pursuant to which Dr. Jayagopal will provide transition services to the Company, as requested by the Company. Dr. Jayagopal will be
compensated for such services at a rate of $250 per hour. Dr. Jayagopal’s outstanding vested options as of the Separation Date will remain exercisable during the term of the consulting arrangement.
The foregoing description of the Letter Agreement does not purport to be complete and is qualified in its entirety by reference to
the text of the Letter Agreement (including the consulting agreement attached as Exhibit A thereto), a copy of which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2026.